Several studies have been done on the myriad list of side effects that come from popular weight loss drugs.  A new study ...

Hims & Hers Health (NYSE:HIMS) has taken investors on a wild ride in 2025. The stock surged nearly 200% earlier this year, reaching an ...

We're one step closer to not just treating baldness but preventing it, with scientists making an important discovery that ...

Taking medications like Ozempic and Wegovy may lead to more hair loss than other weight loss drugs, new research found.

Researchers assessed data from 16 million patients from 2006 to 2020 taking semaglutide-based drugs; the active ingredient in Wegovy.

Finding a hair-loss fix has required ongoing research and trials. As UCLA scientists target a promising treatment option, ...

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents. The knockoff surge was led by Hims & Hers Health, the telehealth firm ...

was curious about the ads he saw promising to reverse his hair loss. He completed a 14-question intake on Hims.com and received a bottle of finasteride pills days later. He never spoke to a doctor.

Currently, Hims & Hers Health, Inc.’s price-earnings ratio is 61.8. Hims & Hers Health, Inc.’s trailing 12-month revenue is $1.5 billion with a 8.5% net profit margin. Year-over-year quarterly sales ...

Year-over-year quarterly sales growth most ... change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%. Acadia Healthcare Company, Inc. has a Momentum ...

Hims & Hers' lower-priced injectable semaglutide promoted during the Super Bowl has led to some patients receiving the more affordable metformin instead. Originally sourced from lilacs, metformin ...